News articles about BiondVax Pharmaceuticals (NASDAQ:BVXV) have trended somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BiondVax Pharmaceuticals earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave news headlines about the company an impact score of 51.332279670007 out of 100, meaning that recent press coverage is somewhat likely to have an effect on the company’s share price in the near term.

Separately, ValuEngine downgraded shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 3rd.

BiondVax Pharmaceuticals (NASDAQ BVXV) traded up $0.06 during mid-day trading on Tuesday, hitting $5.94. 14,900 shares of the company traded hands, compared to its average volume of 15,900. BiondVax Pharmaceuticals has a fifty-two week low of $3.65 and a fifty-two week high of $10.75. The firm has a market capitalization of $38.82 and a P/E ratio of -3.92.

TRADEMARK VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.watchlistnews.com/somewhat-positive-press-coverage-somewhat-likely-to-affect-biondvax-pharmaceuticals-bvxv-stock-price/1800030.html.

BiondVax Pharmaceuticals Company Profile

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Insider Buying and Selling by Quarter for BiondVax Pharmaceuticals (NASDAQ:BVXV)

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.